Home » Stocks » Meridian Bioscience

Meridian Bioscience, Inc. (VIVO)

Stock Price: $24.29 USD -2.12 (-8.03%)
Updated Aug 6, 2020 4:00 PM EDT - Market closed
After-hours: $24.10 -0.19 (-0.78%) Aug 6, 7:59 PM

Stock Price Chart

Key Info

Market Cap 1.04B
Revenue (ttm) 204.00M
Net Income (ttm) 21.37M
Shares Out 42.83M
EPS (ttm) 0.50
PE Ratio 48.58
Forward PE 29.50
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 6, 2020
Last Price $24.29
Previous Close $26.41
Change ($) -2.12
Change (%) -8.03%
Day's Open 26.53
Day's Range 23.52 - 26.58
Day's Volume 591,490
52-Week Range 5.51 - 26.58

More Stats

Market Cap 1.04B
Enterprise Value 1.05B
Earnings Date (est) Aug 7, 2020
Ex-Dividend Date n/a
Shares Outstanding 42.83M
Float 39.20M
EPS (basic) 0.5
EPS (diluted) 0.50
FCF / Share 0.65
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.06%
FCF Yield 2.69%
Payout Ratio n/a
Shares Short 3.10M
Short Ratio 3.27
Short % of Float 8.34%
Beta 0.93
PE Ratio 48.58
Forward PE 29.50
P/FCF Ratio 37.13
PS Ratio 5.10
PB Ratio 5.44
Revenue 204.00M
Operating Income 29.50M
Net Income 21.37M
Free Cash Flow 28.02M
Net Cash -4.74M
Net Cash / Share -0.11
Gross Margin 58.00%
Operating Margin 14.46%
Profit Margin 10.50%
FCF Margin 13.73%
ROA 7.79%
ROE 11.07%
ROIC 19.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (3)

Buy 3
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$26.50*
(9.10% upside)
Low
19.0
Current: $24.29
High
34.0
Target: 26.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue201214201196195189189173159143
Revenue Growth-5.88%6.38%2.39%0.64%3.18%0.08%9.25%8.74%11.07%-
Gross Profit11813112412712211712110998.4188.70
Operating Income32.7031.5837.3851.3856.0652.3957.3149.3040.0341.14
Net Income24.3823.8521.5632.2335.5434.7438.0333.3726.8326.65
Shares Outstanding42.5742.3342.1942.0141.6641.4641.2341.0840.7240.52
Earnings Per Share0.570.560.510.760.850.830.910.800.650.65
EPS Growth1.79%9.8%-32.89%-10.59%2.41%-8.79%13.75%23.08%0%-
Dividend Per Share0.250.500.580.800.800.790.760.760.760.74
Dividend Growth-50%-13.04%-28.13%0%1.27%3.95%0%0%2.7%-
Operating Cash Flow35.8334.7841.3637.2242.8138.2644.4442.4522.4629.73
Capital Expenditures-3.13-4.20-4.47-4.00-3.48-5.31-3.23-3.13-9.14-3.08
Free Cash Flow32.7030.5836.8933.2239.3332.9641.2039.3213.3226.65
Cash & Equivalents62.4060.7658.0748.2350.9744.0545.2832.5924.6338.88
Total Debt75.8250.1854.6558.36------
Net Cash / Debt-13.4310.583.43-10.1350.9744.0545.2832.5924.6338.88
Assets325251250252183177177161155155
Liabilities13575.9680.1985.5617.4115.9021.7018.6316.9717.28
Book Value191175170166166161155143139137
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Meridian Bioscience, Inc.
Country United States
Employees 660
CEO John Patrick Kenny

Stock Information

Ticker Symbol VIVO
Stock Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Unique Identifier NASDAQ: VIVO

Description

Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for various gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms and technologies, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; rapid fluorescence-based immunoassay platform under the Curian brand; rapid single-use immunoassays under the ImmunoCard and ImmunoCard STAT! brand names; enzyme-linked immunoassays under the PREMIER brand; and anodic stripping voltammetry, an electrical chemical sensor platform for quantitative determination under the LeadCare and PediaStat brands. This segment's products are primarily used in the detection of infectious diseases caused by various bacteria, viruses, parasites, and pathogens. Its products consists of gastrointestinal assays, including tests for C. difficile, Enterohemorrhagic E. coli, Campylobacter jejuni, H. pylori, Cryptosporidium, giardia lamblia, and calprotectin; respiratory illness assays, such as tests for Group A Streptococcus, Influenza, M. pneumoniae, Bordetella pertussis, and respiratory syncytial virus; blood chemistry assays; and tests for Group B Streptococcus, Chlamydia trachomatis, Neisseria gonorrhea, Herpes Simplex Virus Type 1 and Type 2, and Malaria. This segment sells its products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories. The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by researchers, agri-bio companies, and IVD manufacturing companies. Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.